in vitro biology Archives - Page 4 of 16

iMN041: Prodrug with a Unique Antitumor Immune Response

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses...

Expanded Applications of PDX Models

Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard...

One Stop Target-to-Hit Platform: STATs

STAT proteins are key mediators of cellular immunity, proliferation, apoptosis, and differentiation. STATs are known to play a role in...

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held...

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished...

Upregulation of drug metabolism enzymes mediates ADC resistance in a HER2-positive cancer cell line

SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant...

Covalent Fragment-based Drug Discovery: BTK Inhibitors

At the Covalent Drug Discovery 2023 Summit and Fragments 2024 Conference, we presented a case study on Bruton’s tyrosine kinase (BTK)...

One Stop Target-to-Hit Platform: Helicases

RecQ helicases (BLM, WRN, RECQL, RECQL4, and RECQL5) are an important family of surveillance proteins that play critical roles in...

One Stop Target-to-Hit Platform: CDKs and CDK-Cyclin Complexes

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer...

Knowledge Library